Rapport Therapeutics, Inc. (RAPP) Form 424B5 — Oct 30, 2026
Rapport Therapeutics (NASDAQ: RAPP) priced a $200 million follow-on offering of 8,333,334 shares at $21.00 per share, a roughly 24% discount to the $27.54 close on October 27, 2026, plus pre-funded warrants on 1,190,476 shares. The offering runs alongside a $150 million 2.25% convertible senior notes offering due 2032 (conversion price ~$26.7750) and a concurrent private placement of 1,428,571 shares at the same $21.00 price, with Morgan Stanley, Leerink Partners, and Evercore ISI leading the deals and a 30-day greenshoe of up to 1,428,571 additional shares.
Key figures
- Debt Amount
- 150000000
- Cash Position
- 436077000
- Interest Rate
- 2.25
- Maturity Date
- 2032-12-01
- Gross Proceeds
- 199998820
- Offering Price
- 21
- Shares Offered
- 8333334
- Shares Outstanding
- 57716984
- Cash runway
- through end of 2029
- Conversion price
- 26.775
- Greenshoe shares
- 1428571
- Prior close oct 27 2026
- 27.54
- Conversion rate per 1000
- 37.3483
- Pre funded warrant price
- 20.999
- As adjusted ntbv per share
- 11.06
- Pre funded warrants shares
- 1190476
- Immediate dilution per share
- 9.94
- Net proceeds convertible notes
- 145000000
- Underwriting discount per share
- 1.26
- Concurrent private placement shares
- 1428571
- Pro forma cash with convertible notes
- 796736000
- Net proceeds offering plus private placement
- 215700000
- Net proceeds offering plus private placement full greenshoe
- 243900000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.